470 related articles for article (PubMed ID: 15958591)
1. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
4. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy.
Fauquembergue E; Toutirais O; Tougeron D; Drouet A; Le Gallo M; Desille M; Cabillic F; de La Pintière CT; Iero M; Rivoltini L; Baert-Desurmont S; Leprince J; Vaudry H; Sesboué R; Frébourg T; Latouche JB; Catros V
J Immunother; 2010 May; 33(4):402-13. PubMed ID: 20386466
[TBL] [Abstract][Full Text] [Related]
5. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells.
Kryukov F; Ocadlíková D; Kovárová L; Buresová I; Hájek R; Michálek J
J Immunotoxicol; 2009 Dec; 6(4):243-8. PubMed ID: 19908943
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
[TBL] [Abstract][Full Text] [Related]
8. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
9. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
Latouche JB; Sadelain M
Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.
Chen L; Liang GP; Tang XD; Chen T; Cai YG; Fang DC; Yu ST; Luo YH; Yang SM
Biochem Biophys Res Commun; 2006 Dec; 351(4):927-34. PubMed ID: 17097054
[TBL] [Abstract][Full Text] [Related]
11. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
12. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
Lu J; Celis E
Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
[TBL] [Abstract][Full Text] [Related]
13. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
14. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
15. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals.
Vonderheide RH; Schultze JL; Anderson KS; Maecker B; Butler MO; Xia Z; Kuroda MJ; von Bergwelt-Baildon MS; Bedor MM; Hoar KM; Schnipper DR; Brooks MW; Letvin NL; Stephans KF; Wucherpfennig KW; Hahn WC; Nadler LM
Cancer Res; 2001 Dec; 61(23):8366-70. PubMed ID: 11731409
[TBL] [Abstract][Full Text] [Related]
16. Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT.
Tong XM; Zheng SE; Bader A; Yao HP; Wu NP; Altmeyer P; Brockmeyer NH; Jin J
Eur J Med Res; 2008 Jan; 13(1):7-14. PubMed ID: 18226991
[TBL] [Abstract][Full Text] [Related]
17. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
18. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
19. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
[TBL] [Abstract][Full Text] [Related]
20. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]